Treatment Targets Show Promise in Psoriatic Arthritis and RA
Jan 23, 2018
New data highlight the role of the C5a-C5aR axis in the onset of inflammation.
Expanded role for MRI and 2 recently approved treatment options. (©Gemalbarra/Shutterstock.com)
Psoriatic Arthritis
What Remains of Psoriatic Arthritis After Treatment
Jan 23, 2018
Moderate to high disease activity may persist.
5 New Medications for Rheumatology
Dec 22, 2017
Here’s a brief look at medications for rheumatologic disorders that were newly approved in the last quarter of 2017.
FDA Gives Nod to Tofacitinib for Active Psoriatic Arthritis
Dec 20, 2017
The first oral JAK inhibitor approved for both moderate to severe RA and active PsA.
Ixekizumab Gets FDA Nod for Active Psoriatic Arthritis
Dec 11, 2017
Psoriatic arthritis is the second approved indication for Taltz in the United States.
Tofacitinib is Effective in Psoriatic Arthritis
Nov 20, 2017
This agent was superior to placebo in patients who had not responded to or could not take a conventional DMARD.
Golimumab FDA Approved for Psoriatic Arthritis, Ankylosing Spondylitis
Oct 23, 2017
This is the only fully human anti-TNF-α infused therapy approved for psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.
Physicians Forgo Psoriatic Arthritis Treatment Adjustments
Oct 17, 2017
Residual disease activity is common, and treatment options abound, but for most patients changes are not being made.
Psoriatic Arthritis Damage Marked by Enthesitis Severity
Sep 5, 2017
Sonographic enthesitis severity is a potential marker of radiographic peripheral and axial joint damage.
Orencia Gains Psoriatic Arthritis Approval in Europe
Aug 2, 2017
Patients demonstrated improved disease response in 2 clinical trials.
